Neuromuscular Research Funding Announcements From Jesse’s Journey and Muscular Dystrophy Canada
The NMD4C is excited to share recent grant funding announcements from two of our partners, Jesse’s Journey and Muscular Dystrophy Canada. The network is incredibly fortunate to be able to collaborate with these incredible organizations, and it is our pleasure to recognize the contributions of each towards helping to fund neuromuscular research.
Jesse’s Journey
Jesse’s Journey, Canada’s leader in Duchenne muscular dystrophy funded research, will grant $1.7M toward four promising research projects this year – the largest annual amount in its 26-year history.
Newly funded projects in 2021 include:
Dr. Niclas Bengtsson: Development of gene regulatory cassettes that enable safe- and efficient in vivo dystrophin gene-editing in muscle stem cells.
Dr. Natasha Chang: Inducing stress granule formation in muscle stem cells to treat DMD.
Dr. Ronald Cohn: Simultaneous DMD gene editing and upregulation to restore protective levels of full-length dystrophin in the treatment of DMD duplication mutations.
Dr. Sachiko Sato: Development of a Monosaccharide Therapy Using N-Acetylglucosamine to Mitigate Duchenne Muscular Dystrophy.
The growth in scientific funding interest is encouraging for the community because it means there is an increasing commitment to Duchenne science and drug discovery, bringing hope and progress towards prevention, treatment, and ultimately – a cure.
Read the full press release from Jesse’s Journey here!
Muscular Dystrophy Canada
Muscular Dystrophy Canada (MDC) has announced an investment of $400,000 to fund seven new research projects in 2021 through the MDC Neuromuscular Disorder (NMD) Research Grant Competition, a dedicated Canadian source of funding for neuromuscular research. MDC will also invest in an international, collaborative, $1.15 million, research project through the European Joint Programme on Rare Diseases (EJP RD).
The 2020-2021 research grant recipients are:
Dr. Alex Parker: A Pharmacogenetic Pipeline for Charcot-Marie-Tooth Disease
Dr. Colin Crist: Promoting Muscle Repair by Pharmacological Inhibition of eIF2a Dephosphorylation
Dr. Mohamed Chahine: Human iPSC-derived Neurons as a Model of Congenital Myotonic Dystrophy Type 1
Dr. Nadine Wiper-Bergeron: Improving Myoblast Transplantation Outcomes via Pharmacological Reprogramming
Dr. Nicolas Dumont: Targeting Defective Stem Cells in a Preclinical Model of Myotonic Dystrophy Type 1
Dr. Rima Al-Awar (EJPRD/CIHR Co-funded): Safety and Efficacy of a Possible Epigenetic Therapy for Facioscapulohumeral Muscular Dystrophy
Dr. Toshifumi Yokota: Enhancing the Efficacy of Antisense Oligonucleotide Therapy for Facioscapulohumeral Muscular Dystrophy
Read the full press release from Muscular Dystrophy Canada here!
Read next...
Applications Open for New NMD4C Collaborative Research Training Awards!
The NMD4C is excited to announce a new program for neuromuscular research trainees that will support collaboration opportunities between Canadian research labs.
NMD4C Members Receive Dr David Green Awards from Muscular Dystrophy Canada
We are excited to share that several NMD4C investigators and members have been honored with a Dr David Green Award from Muscular Dystrophy Canada!
Lower Extremity Muscle Strengthening Program in Myotonic Dystrophy Type 1 from Groupe de recherche interdisciplinaire sur les maladies neuromusculaires
The Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN) recently created a video aimed at health professionals that provides an in-depth explanation of the Myotonic dystrophy (DM1) training parameters used in their studies.
Fifth Annual Clinical Fellowship Competition from NMD4C and MDC Opens May 1st
The NMD4C and MDC clinical neuromuscular fellowship competition is accepting applications for the 2026 competition until June 12, 2025.
